Report cover image

Global Vaccines Market, 2025-2033

Publisher PreciseView Reports
Published Oct 11, 2025
Length 444 Pages
SKU # PCSR20630881

Description

Global Vaccines Market, valued at USD 58.7 billion in 2024, is poised to advance to USD 102.4 billion by 2033, demonstrating steady CAGR of 6.4% across the 2025-2033 horizon. This trajectory is energized by escalating infectious disease threats with vaccination coverage exceeding billions annually, burgeoning pediatric and adult immunization programs worldwide, and strides in mRNA and viral vector technologies yielding 7% CAGR for quicker development and broader efficacy across disease indications. Acceleration has marked the sector since 2021, propelled by urgent COVID-19 responses, heightened global health investments, and a 14% surge in therapeutic vaccine sales driven by Europe's oncology sector innovations. Pivotal patterns spotlight mRNA vaccines' dominance for adaptability and rapid deployment, multivalent formulations commanding efficiency for combined protection, and intramuscular route establishing standard administration, with COVID-19 applications emerging for ongoing variant management. Viable gateways include Asia Pacific's vast production ecosystem notably India's affordable conjugate vaccine calls for pediatric immunization scale, North America's advanced healthcare infrastructure fueling adult vaccination programs, and Europe's robust R&D and precision medicine trends in therapeutic vaccines. Yet, headwinds persist with hefty development and approval costs curbing innovation in price-sensitive Latin American markets, cold chain and logistics complexities impacting distribution in developing regions, and vaccine hesitancy and misinformation complicating government program uptake. Asia Pacific grips over 40% dominion, anchored by India's production capacity and export leadership, while Europe charges ahead at 7.0% CAGR, invigorated by robust R&D investments and vaccination drive pipelines.

Tailored breakdowns unlock targeted plays across vaccine types, disease indications, valence formats, administration routes, end-user demographics, and terrains. Types crown mRNA for responsiveness, disease indications lean COVID-19 for volume and urgency, valence bet multivalent for efficiency gains, routes spotlight intramuscular for scalability, and end-users emphasize pediatric for foundational immunity, with locale-specific edges – Asia Pacific for expanse and affordability, Europe for velocity and innovation, and North America for infrastructure excellence.

Market Segmentation:


By Type:

Conjugate Vaccines
Recombinant Vaccines
Inactivated Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
mRNA Vaccines
Viral Vector Vaccines
Others

By Disease Indication:

Hepatitis
Human Papillomavirus (HPV)
Influenza
Measles, Mumps, Rubella (MMR)
Rotavirus
COVID-19
Pneumococcal Disease
Others

By Valence:

Monovalent
Multivalent

By Route of Administration:

Intramuscular
Subcutaneous
Oral
Intradermal
Others

By End-User:

Pediatric
Adult

By Region:

North America (United States, Canada, Others)
Europe (United Kingdom, Germany, France, Italy, Spain, Others)
Asia Pacific (China, Japan, India, South Korea, Australia, Others)
Latin America (Brazil, Others)
Middle East & Africa (United Arab Emirates, Others)

Please note:Delivery Timeline: 2-3 Business Days

Table of Contents

444 Pages
Research Objective
MARKET SEGMENTATION
Scope of the Study
Key Questions Answered in the Report
Chapter 1 Research Methodology
1.1 Research Objective
1.2 Market Research Process
1.2.1 Data Procurement and Data Mining
1.2.2 Data Analysis and Standardization
1.2.3 Data Processing and Market Formulation
1.2.4 Data Validation
1.3 Market Research Approach
1.3.1 Residential Research
1.3.2 Commercial Research
1.3.3 Assumptions & Limitations
1.4 Year Considered for the Study
Chapter 2 Executive Summary
2.1 Global Vaccines Market Snapshot
2.2 Global Vaccines Market
Chapter 3 Market Variables and Scope
3.1 Introduction to Vaccines
3.2 Classification and Scope
Chapter 4 Market Dynamics and Trends
4.1 Global Vaccines Market Dynamics
4.2 Global Vaccines Market Dynamics, Impact Analysis
4.3 Market Drivers
4.3.1 Driver 1
4.3.2 Driver 2
4.4 Market Restraints
4.4.1 Restraint 1
4.4.2 Restraint 2
4.5 Market Opportunity
4.5.1 Opportunity 1
4.5.2 Opportunity 2
Chapter 5 Premium Insights
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of Substitute Types
5.1.4 Rivalry among Existing Firms
5.1.5 Threat of New Entrants
5.2 Supply Chain Analysis
5.3 Market Share Analysis of Key Players, 2024
5.4 Market Entry Strategy Assessment
5.5 Strategic Recommendation for Stakeholders
Chapter 6 Global Vaccines Market, By Type
6.1 Global Vaccines Market, By Type, 2025 - 2033
6.2 Conjugate Vaccines
6.3 Recombinant Vaccines
6.4 Inactivated Vaccines
6.5 Live Attenuated Vaccines
6.6 Toxoid Vaccines
6.7 mRNA Vaccines
6.8 Viral Vector Vaccines
6.9 Others
Chapter 7 Global Vaccines Market, By Disease Indication
7.1 Global Vaccines Market, By Disease Indication, 2025 - 2033
7.2 Hepatitis
7.3 Human Papillomavirus (HPV)
7.4 Influenza
7.5 Measles, Mumps, Rubella (MMR)
7.6 Rotavirus
7.7 COVID-19
7.8 Pneumococcal Disease
7.9 Others
Chapter 8 Global Vaccines Market, By Valence
8.1 Global Vaccines Market, By Valence, 2025 - 2033
8.2 Monovalent
8.3 Multivalent
Chapter 9 Global Vaccines Market, By Route of Administration
9.1 Global Vaccines Market, By Route of Administration, 2025 - 2033
9.2 Intramuscular
9.3 Subcutaneous
9.4 Oral
9.5 Intradermal
9.6 Others
Chapter 10 Global Vaccines Market, By End-User
10.1 Global Vaccines Market, By End-User, 2025 - 2033
10.2 Pediatric
10.3 Adult
Chapter 11 Global Vaccines Market, By Region
11.1 Overview
11.2 North America
11.2.1 North America Vaccines Market, By Country
11.2.2 North America Vaccines Market, By Type
11.2.3 North America Vaccines Market, By Disease Indication
11.2.4 North America Vaccines Market, By Valence
11.2.5 North America Vaccines Market, By Route of Administration
11.2.6 North America Vaccines Market, By End-User
11.2.7 United States
11.2.7.1 United States Vaccines Market, By Type
11.2.7.2 United States Vaccines Market, By Disease Indication
11.2.7.3 United States Vaccines Market, By Valence
11.2.7.4 United States Vaccines Market, By Route of Administration
11.2.7.5 United States Vaccines Market, By End-User
11.2.8 Canada
11.2.8.1 Canada Vaccines Market, By Type
11.2.8.2 Canada Vaccines Market, By Disease Indication
11.2.8.3 Canada Vaccines Market, By Valence
11.2.8.4 Canada Vaccines Market, By Route of Administration
11.2.8.5 Canada Vaccines Market, By End-User
11.2.9 Others
11.2.9.1 Others Vaccines Market, By Type
11.2.9.2 Others Vaccines Market, By Disease Indication
11.2.9.3 Others Vaccines Market, By Valence
11.2.9.4 Others Vaccines Market, By Route of Administration
11.2.9.5 Others Vaccines Market, By End-User
11.3 Europe
11.3.1 Europe Vaccines Market, By Country
11.3.2 Europe Vaccines Market, By Type
11.3.3 Europe Vaccines Market, By Disease Indication
11.3.4 Europe Vaccines Market, By Valence
11.3.5 Europe Vaccines Market, By Route of Administration
11.3.6 Europe Vaccines Market, By End-User
11.3.7 United Kingdom
11.3.7.1 United Kingdom Vaccines Market, By Type
11.3.7.2 United Kingdom Vaccines Market, By Disease Indication
11.3.7.3 United Kingdom Vaccines Market, By Valence
11.3.7.4 United Kingdom Vaccines Market, By Route of Administration
11.3.7.5 United Kingdom Vaccines Market, By End-User
11.3.8 Germany
11.3.8.1 Germany Vaccines Market, By Type
11.3.8.2 Germany Vaccines Market, By Disease Indication
11.3.8.3 Germany Vaccines Market, By Valence
11.3.8.4 Germany Vaccines Market, By Route of Administration
11.3.8.5 Germany Vaccines Market, By End-User
11.3.9 France
11.3.9.1 France Vaccines Market, By Type
11.3.9.2 France Vaccines Market, By Disease Indication
11.3.9.3 France Vaccines Market, By Valence
11.3.9.4 France Vaccines Market, By Route of Administration
11.3.9.5 France Vaccines Market, By End-User
11.3.10 Italy
11.3.10.1 Italy Vaccines Market, By Type
11.3.10.2 Italy Vaccines Market, By Disease Indication
11.3.10.3 Italy Vaccines Market, By Valence
11.3.10.4 Italy Vaccines Market, By Route of Administration
11.3.10.5 Italy Vaccines Market, By End-User
11.3.11 Spain
11.3.11.1 Spain Vaccines Market, By Type
11.3.11.2 Spain Vaccines Market, By Disease Indication
11.3.11.3 Spain Vaccines Market, By Valence
11.3.11.4 Spain Vaccines Market, By Route of Administration
11.3.11.5 Spain Vaccines Market, By End-User
11.3.12 Others
11.3.12.1 Others Vaccines Market, By Type
11.3.12.2 Others Vaccines Market, By Disease Indication
11.3.12.3 Others Vaccines Market, By Valence
11.3.12.4 Others Vaccines Market, By Route of Administration
11.3.12.5 Others Vaccines Market, By End-User
11.4 Asia Pacific
11.4.1 Asia Pacific Vaccines Market, By Country
11.4.2 Asia Pacific Vaccines Market, By Type
11.4.3 Asia Pacific Vaccines Market, By Disease Indication
11.4.4 Asia Pacific Vaccines Market, By Valence
11.4.5 Asia Pacific Vaccines Market, By Route of Administration
11.4.6 Asia Pacific Vaccines Market, By End-User
11.4.7 China
11.4.7.1 China Vaccines Market, By Type
11.4.7.2 China Vaccines Market, By Disease Indication
11.4.7.3 China Vaccines Market, By Valence
11.4.7.4 China Vaccines Market, By Route of Administration
11.4.7.5 China Vaccines Market, By End-User
11.4.8 Japan
11.4.8.1 Japan Vaccines Market, By Type
11.4.8.2 Japan Vaccines Market, By Disease Indication
11.4.8.3 Japan Vaccines Market, By Valence
11.4.8.4 Japan Vaccines Market, By Route of Administration
11.4.8.5 Japan Vaccines Market, By End-User
11.4.9 India
11.4.9.1 India Vaccines Market, By Type
11.4.9.2 India Vaccines Market, By Disease Indication
11.4.9.3 India Vaccines Market, By Valence
11.4.9.4 India Vaccines Market, By Route of Administration
11.4.9.5 India Vaccines Market, By End-User
11.4.10 South Korea
11.4.10.1 South Korea Vaccines Market, By Type
11.4.10.2 South Korea Vaccines Market, By Disease Indication
11.4.10.3 South Korea Vaccines Market, By Valence
11.4.10.4 South Korea Vaccines Market, By Route of Administration
11.4.10.5 South Korea Vaccines Market, By End-User
11.4.11 Australia
11.4.11.1 Australia Vaccines Market, By Type
11.4.11.2 Australia Vaccines Market, By Disease Indication
11.4.11.3 Australia Vaccines Market, By Valence
11.4.11.4 Australia Vaccines Market, By Route of Administration
11.4.11.5 Australia Vaccines Market, By End-User
11.4.12 Others
11.4.12.1 Others Vaccines Market, By Type
11.4.12.2 Others Vaccines Market, By Disease Indication
11.4.12.3 Others Vaccines Market, By Valence
11.4.12.4 Others Vaccines Market, By Route of Administration
11.4.12.5 Others Vaccines Market, By End-User
11.5 Latin America
11.5.1 Latin America Vaccines Market, By Country
11.5.2 Latin America Vaccines Market, By Type
11.5.3 Latin America Vaccines Market, By Disease Indication
11.5.4 Latin America Vaccines Market, By Valence
11.5.5 Latin America Vaccines Market, By Route of Administration
11.5.6 Latin America Vaccines Market, By End-User
11.5.7 Brazil
11.5.7.1 Brazil Vaccines Market, By Type
11.5.7.2 Brazil Vaccines Market, By Disease Indication
11.5.7.3 Brazil Vaccines Market, By Valence
11.5.7.4 Brazil Vaccines Market, By Route of Administration
11.5.7.5 Brazil Vaccines Market, By End-User
11.5.8 Others
11.5.8.1 Others Vaccines Market, By Type
11.5.8.2 Others Vaccines Market, By Disease Indication
11.5.8.3 Others Vaccines Market, By Valence
11.5.8.4 Others Vaccines Market, By Route of Administration
11.5.8.5 Others Vaccines Market, By End-User
11.6 Middle East and Africa (MEA)
11.6.1 Middle East and Africa (MEA) Vaccines Market, By Country
11.6.2 Middle East and Africa (MEA) Vaccines Market, By Type
11.6.3 Middle East and Africa (MEA) Vaccines Market, By Disease Indication
11.6.4 Middle East and Africa (MEA) Vaccines Market, By Valence
11.6.5 Middle East and Africa (MEA) Vaccines Market, By Route of Administration
11.6.6 Middle East and Africa (MEA) Vaccines Market, By End-User
11.6.7 United Arab Emirates
11.6.7.1 United Arab Emirates Vaccines Market, By Type
11.6.7.2 United Arab Emirates Vaccines Market, By Disease Indication
11.6.7.3 United Arab Emirates Vaccines Market, By Valence
11.6.7.4 United Arab Emirates Vaccines Market, By Route of Administration
11.6.7.5 United Arab Emirates Vaccines Market, By End-User
11.6.8 Others
11.6.8.1 Others Vaccines Market, By Type
11.6.8.2 Others Vaccines Market, By Disease Indication
11.6.8.3 Others Vaccines Market, By Valence
11.6.8.4 Others Vaccines Market, By Route of Administration
11.6.8.5 Others Vaccines Market, By End-User
Chapter 12 Competitive Landscape
12.1 Strategic Move Analysis
12.1.1 Top Player Positioning/Market Share Analysis
12.1.2 Top Winning Strategies, By Year, 2021-2024
12.1.3 Competitive Analysis by Revenue, 2022-2024
12.2 Recent Developments by the Market Participants (2024-25)
Chapter 13 Company Profiles
13.1 Pfizer Inc.
13.1.1 Company Snapshot
13.1.2 Company Overview
13.1.3 Financial Performance
13.1.4 Product Portfolio
13.1.5 Strategic Growth
13.2 Moderna Inc.
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Performance
13.2.4 Product Portfolio
13.2.5 Strategic Growth
13.3 GlaxoSmithKline plc (GSK)
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Performance
13.3.4 Product Portfolio
13.3.5 Strategic Growth
13.4 Sanofi S.A.
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Performance
13.4.4 Product Portfolio
13.4.5 Strategic Growth
13.5 Merck & Co. Inc.
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Performance
13.5.4 Product Portfolio
13.5.5 Strategic Growth
13.6 AstraZeneca plc
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Performance
13.6.4 Product Portfolio
13.6.5 Strategic Growth
13.7 Johnson & Johnson
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Performance
13.7.4 Product Portfolio
13.7.5 Strategic Growth
13.8 Novavax Inc.
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Performance
13.8.4 Product Portfolio
13.8.5 Strategic Growth
13.9 Bharat Biotech International Limited
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Performance
13.9.4 Product Portfolio
13.9.5 Strategic Growth
13.10 Serum Institute of India Pvt. Ltd.
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Financial Performance
13.10.4 Product Portfolio
13.10.5 Strategic Growth
13.11 Sinovac Biotech Ltd.
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Performance
13.11.4 Product Portfolio
13.11.5 Strategic Growth
13.12 BioNTech SE
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Performance
13.12.4 Product Portfolio
13.12.5 Strategic Growth
13.13 CSL Limited
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Performance
13.13.4 Product Portfolio
13.13.5 Strategic Growth
13.14 Valneva SE
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Performance
13.14.4 Product Portfolio
13.14.5 Strategic Growth
13.15 Sinopharm Group Co. Ltd.
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Financial Performance
13.15.4 Product Portfolio
13.15.5 Strategic Growth

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us